SG Americas Securities LLC Buys New Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,333 shares of the company’s stock, valued at approximately $112,000.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Octagon Capital Advisors LP raised its position in Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after buying an additional 74,000 shares during the last quarter. Vestal Point Capital LP acquired a new stake in Dianthus Therapeutics during the 4th quarter valued at approximately $1,404,000. Janus Henderson Group PLC purchased a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at $11,251,000. Finally, Virtu Financial LLC acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth $390,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, August 12th. Cantor Fitzgerald started coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating for the company. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $44.71.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $29.78 on Tuesday. The firm has a market cap of $874.01 million, a PE ratio of -5.11 and a beta of 1.89. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77. The firm has a fifty day moving average of $27.46 and a 200 day moving average of $25.71.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. On average, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.